Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 206 vs Nivolumab in Resected Advanced Melanoma
NCT05907122Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2023
- Primary completion
- Mar 2025
- Modality
- Intravenous therapy
- Countries
- 22
01
Overview
A Phase 3 trial of ABP 206 in melanoma, sponsored by Amgen. Started Jul 2023; status: completed.
02
Drugs
ABP 206
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05907122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907122.